<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744444</url>
  </required_header>
  <id_info>
    <org_study_id>2012.737</org_study_id>
    <nct_id>NCT01744444</nct_id>
  </id_info>
  <brief_title>Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different treatment trials have been published in acquired nystagmus in the last decade;&#xD;
      gabapentin and memantine have been found to be efficient in treating pendular nystagmus in&#xD;
      Multiple Sclerosis. The effects of treatments are measured on nystagmus velocity, amplitude,&#xD;
      frequency and on visual acuity. None of the trials measured a functional visual score or&#xD;
      oscillopsia score.&#xD;
&#xD;
      The aim of our study is to evaluate the effect of gabapentin and memantine on the mean&#xD;
      velocity, amplitude and frequency of pendular nystagmus, as well as on oscillopsia, visual&#xD;
      acuity and vision-specific health-related quality of life score, in 10 patients with multiple&#xD;
      sclerosis. The primary object is to find out the best variable to evaluate the efficiency of&#xD;
      nystagmus treatment and the secondary, to compare the efficiency of both gabapentin and&#xD;
      memantine in a common population of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Velocity using eye movement recording</measure>
    <time_frame>at Day17-21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Velocity using eye movement recording</measure>
    <time_frame>at Day34-42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Velocity using eye movement recording</measure>
    <time_frame>at Day64-79</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Velocity using eye movement recording</measure>
    <time_frame>at Day81-100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional score on questioning</measure>
    <time_frame>at Day17-21, Day34-42, Day64-79, Day81-100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective measure of oscillopsia</measure>
    <time_frame>at Day17-21, Day34-42, Day64-79, Day81-100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Far visual acuity</measure>
    <time_frame>at Day17-21, Day34-42, Day64-79, Day81-100</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pendular Nystagmus Patients With Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Memantine first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gabapentin first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.</description>
    <arm_group_label>Memantine first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.</description>
    <arm_group_label>Gabapentin first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients may have a clinically definite, laboratory-supported diagnosis of&#xD;
             multiple sclerosis according to the Mac Donald criteria.&#xD;
&#xD;
          -  All patients may present a chronic acquired pendular nystagmus due to MS, observed&#xD;
             over a period of 6 months.&#xD;
&#xD;
          -  All patients will be informed about the design and purpose of the study, and all will&#xD;
             give their informed, written consent to the protocol, which may have been approved by&#xD;
             the local ethics committee.&#xD;
&#xD;
          -  Age: above 18&#xD;
&#xD;
          -  Able to understand the instructions&#xD;
&#xD;
          -  Having a health coverage&#xD;
&#xD;
          -  Able to sit down for 1 hour&#xD;
&#xD;
          -  Stable dosage of previous medications (beginning 3 weeks previously and terminating at&#xD;
             the end of the trial duration), except for steroids, gabapentin or memantine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ophthalmological&#xD;
&#xD;
               -  Other ophthalmological disorder that could impair corrected visual acuity&#xD;
                  (Maculopathy, Retinopathy…)&#xD;
&#xD;
          -  Neurological&#xD;
&#xD;
               -  Ongoing seizure&#xD;
&#xD;
               -  Severe handicap that does not allow sitting down position for 1 hour&#xD;
&#xD;
          -  Suicidal behavior or risk&#xD;
&#xD;
          -  Treatment&#xD;
&#xD;
               -  Under memantine or gabapentin medication (these medications should have been&#xD;
                  stopped for at least 1 week for gabapentin and 3 weeks for memantine)&#xD;
&#xD;
               -  Under morphine, N-methyl-D-aspartate such as amantadine, ketamine or&#xD;
                  dextromethorphan&#xD;
&#xD;
               -  Steroid medication for a current relapse (beginning 3 weeks previously and&#xD;
                  terminating at the end of the trial duration)&#xD;
&#xD;
               -  Known hypersensitivity to memantine or gabapentin&#xD;
&#xD;
          -  General&#xD;
&#xD;
               -  Unstable medical state&#xD;
&#xD;
               -  Patient with a galactose intolerance, a lapp lactase deficiency or&#xD;
                  glucose-galactose malabsorption&#xD;
&#xD;
               -  Moderate renal failure (creatinine clearance &lt; 50 mL/min on bioassay dated from&#xD;
                  less than one month)&#xD;
&#xD;
               -  Recent heart infarction (&lt;3months)&#xD;
&#xD;
               -  Unstable congestive heart insufficiency&#xD;
&#xD;
               -  Unstable arterial hypertension&#xD;
&#xD;
               -  Leucopenia (&lt;2500/mm3)&#xD;
&#xD;
               -  Transaminase increase (&gt;5 time normal values)&#xD;
&#xD;
          -  Pregnancy (on questioning)&#xD;
&#xD;
          -  Tutelage or any legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Tilikete, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Neurologique Unité de Neuro-Ophtalmologie</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>November 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nystagmus, Pathologic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

